This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Impact and cost-effectiveness of an injectable rotavirus vaccine candidate compared to oral rotavirus vaccines

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.

Publication date: October 2021

Impact and cost-effectiveness of an injectable rotavirus vaccine candidate compared to oral rotavirus vaccines

234.6 KB PDF
View Resource